Literature DB >> 22910979

Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma.

Anne Lynn S Chang, Anthony E Oro.   

Abstract

Entities:  

Year:  2012        PMID： 22910979      PMCID： PMC3777384          DOI： 10.1001/archdermatol.2012.2354

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN： 0003-987X


× No keyword cloud information.
  5 in total

Review 1.  Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists.

Authors:  Ciara Metcalfe; Frederic J de Sauvage
Journal:  Cancer Res       Date:  2011-07-19       Impact factor: 12.701

2.  Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.

Authors:  Gerrit J P Dijkgraaf; Bruno Alicke; Lasse Weinmann; Thomas Januario; Kristina West; Zora Modrusan; Dan Burdick; Richard Goldsmith; Kirk Robarge; Dan Sutherlin; Suzie J Scales; Stephen E Gould; Robert L Yauch; Frederic J de Sauvage
Journal:  Cancer Res       Date:  2010-12-01       Impact factor: 12.701

3.  Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

Authors:  Patricia M LoRusso; Charles M Rudin; Josina C Reddy; Raoul Tibes; Glen J Weiss; Mitesh J Borad; Christine L Hann; Julie R Brahmer; Ilsung Chang; Walter C Darbonne; Richard A Graham; Kenn L Zerivitz; Jennifer A Low; Daniel D Von Hoff
Journal:  Clin Cancer Res       Date:  2011-02-07       Impact factor: 12.531

4.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

Authors:  Aleksandar Sekulic; Michael R Migden; Anthony E Oro; Luc Dirix; Karl D Lewis; John D Hainsworth; James A Solomon; Simon Yoo; Sarah T Arron; Philip A Friedlander; Ellen Marmur; Charles M Rudin; Anne Lynn S Chang; Jennifer A Low; Howard M Mackey; Robert L Yauch; Richard A Graham; Josina C Reddy; Axel Hauschild
Journal:  N Engl J Med       Date:  2012-06-07       Impact factor: 91.245

5.  Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.

Authors:  Daniel D Von Hoff; Patricia M LoRusso; Charles M Rudin; Josina C Reddy; Robert L Yauch; Raoul Tibes; Glen J Weiss; Mitesh J Borad; Christine L Hann; Julie R Brahmer; Howard M Mackey; Bertram L Lum; Walter C Darbonne; James C Marsters; Frederic J de Sauvage; Jennifer A Low
Journal:  N Engl J Med       Date:  2009-09-02       Impact factor: 91.245
  5 in total
  54 in total

1.  Long-term Response to Vismodegib in a Patient with Gorlin-Goltz Syndrome: A Case Report and Review of Pathological Mechanisms Involved.

Authors:  Meghana Kesireddy; Vincent L Mendiola; Bagi Jana; Shrestha Patel
Journal:  Cureus       Date:  2019-08-13

Review 2.  Unraveling the therapeutic potential of the Hedgehog pathway in cancer.

Authors:  Dereck Amakye; Zainab Jagani; Marion Dorsch
Journal:  Nat Med       Date:  2013-11-07       Impact factor: 53.440

Review 3.  Diagnosis and Management of Basal Cell Carcinoma.

Authors:  Keiji Tanese
Journal:  Curr Treat Options Oncol       Date:  2019-02-11

Review 4.  Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.

Authors:  Erica Leavitt; Gary Lask; Stephanie Martin
Journal:  Curr Treat Options Oncol       Date:  2019-11-26

5.  Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.

Authors:  Hayley J Sharpe; Gregoire Pau; Gerrit J Dijkgraaf; Nicole Basset-Seguin; Zora Modrusan; Thomas Januario; Vickie Tsui; Alison B Durham; Andrzej A Dlugosz; Peter M Haverty; Richard Bourgon; Jean Y Tang; Kavita Y Sarin; Luc Dirix; David C Fisher; Charles M Rudin; Howard Sofen; Michael R Migden; Robert L Yauch; Frederic J de Sauvage
Journal:  Cancer Cell       Date:  2015-03-09       Impact factor: 31.743

Review 6.  Vismodegib: A Review in Advanced Basal Cell Carcinoma.

Authors:  James E Frampton; Nicole Basset-Séguin
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

7.  Tumor Architecture and Notch Signaling Modulate Drug Response in Basal Cell Carcinoma.

Authors:  Markus Eberl; Doris Mangelberger; Jacob B Swanson; Monique E Verhaegen; Paul W Harms; Marcus L Frohm; Andrzej A Dlugosz; Sunny Y Wong
Journal:  Cancer Cell       Date:  2018-01-27       Impact factor: 31.743

8.  Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma.

Authors:  François Kuonen; Noelle E Huskey; Gautam Shankar; Prajakta Jaju; Ramon J Whitson; Kerri E Rieger; Scott X Atwood; Kavita Y Sarin; Anthony E Oro
Journal:  J Invest Dermatol       Date:  2019-01-29       Impact factor: 8.551

9.  Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.

Authors:  Ximena Bonilla; Laurent Parmentier; Bryan King; Fedor Bezrukov; Gürkan Kaya; Vincent Zoete; Vladimir B Seplyarskiy; Hayley J Sharpe; Thomas McKee; Audrey Letourneau; Pascale G Ribaux; Konstantin Popadin; Nicole Basset-Seguin; Rouaa Ben Chaabene; Federico A Santoni; Maria A Andrianova; Michel Guipponi; Marco Garieri; Carole Verdan; Kerstin Grosdemange; Olga Sumara; Martin Eilers; Iannis Aifantis; Olivier Michielin; Frederic J de Sauvage; Stylianos E Antonarakis; Sergey I Nikolaev
Journal:  Nat Genet       Date:  2016-03-07       Impact factor: 38.330

10.  Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome.

Authors:  Anne Lynn S Chang; Scott X Atwood; Danielle M Tartar; Anthony E Oro
Journal:  JAMA Dermatol       Date:  2013-05       Impact factor: 10.282
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.